Home > Drugs A – Z > Carvedilol (By mouth)

Carvedilol (By mouth)

Treats high blood pressure and heart failure. Also reduces the risk of death after a heart attack. This medicine is a beta-blocker.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Carvedilol is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure… Read more
Brand names include
Carvedilol, Coreg, Coreg CR
Drug classes About this
Antianginal, Antihypertensive, Cardiovascular Agent

What works? Research summarized

Evidence reviews

Carvedilol versus metoprolol for primary hypertension: a systematic review

Bibliographic details: Niu XW, Xu H, He SL, Chen D, Yan D, He ZY, Yao YL.  Carvedilol versus metoprolol for primary hypertension: a systematic review. Chinese Journal of Evidence-Based Medicine 2013; 13(8): 963-970

Beta-blockers (carvedilol) in children with systemic ventricle systolic dysfunction - systematic review and meta-analysis

Background.Numerous prospective randomized clinical trials demonstrated favorable effect of beta-blockers in adults with chronic heart failure. However, effectiveness of beta blockers in pediatric patients with systemic ventricle systolic dysfunction was not recognized sufficiently. Limited number of pediatric patients might be the course of unrecognized carvediolol treatment benefit. Currently, no meta-analysis has examined the impact of carvedilol and conventional therapy on the clinical outcome in children with chronic heart failure due to impaired systemic ventricle systolic function. Materials and Methods.We have systematically searched the Medline/PubMed and Cochrane Library for the controlled clinical trials that examine carvedilol and standard treatment efficacy in pediatric patients with systemic ventricle systolic dysfunction. Mean differences for continuous variables, odds ratios for dichotomous outcomes, heterogeneity between studies and publication bias were calculated using Cochrane Review Manager (Rev Man 5.2). Results. Total of 8 prospective/observational studies met established criteria. Odds ratio for chronic heart failure related mortality/heart transplantation secondary to carvedilol was 0.57 (95% CI: 0.33-0.97, I(2) = 0%). Our analysis showed that carvedilol could prevent 1 death/ heart transplantation by treating 17 pediatric patients with impaired systemic ventricle systolic function. Conclusion. Meta-analysis demonstrated clinical outcome benefit of carvedilol in children with chronic heart failure.

Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).

Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings. A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF. Compared to β(1)-selective BBs used in HF (8 trials, n = 4,563), carvedilol significantly reduced all-cause mortality (risk ratio 0.85, 95% confidence interval 0.78 to 0.93, p = 0.0006). In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16). In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients. Additionally, carvedilol significantly reduced all-cause mortality compared with β(1)-selective BBs in AMI patients using the fixed-effects model but not using the random-effects model.

See all (53)

Summaries for consumers

Comparing Beta Blockers

How do beta blockers compare in hypertension?

Beta‐blockers for children with congestive heart failure

The term congestive heart failure describes a disorder in which the heart is unable to sufficiently and efficiently pump blood through the body. Depending on the severity of the condition, this causes breathlessness and fatigue due to insufficient oxygen supply, and an accumulation of fluids in tissues and organs.

Alpha and beta dual receptor blockers for treatment of high blood pressure

Alpha and beta dual receptor blockers are a subclass of beta blockers which are commonly used to treat high blood pressure (BP). Drugs in this class include carvedilol (Coreg), labetalol (Trandate) and dilevalol (Unicard). We searched for and found all the relevant studies to examine how well this class of drugs lowered blood pressure.

See all (5)

PubMed Health Blog...

read all...